About Centrient Pharmaceuticals India Private Limited
Data last updated:
Centrient Pharmaceuticals India Private Limited is a private limited company based in Toansa, Punjab, India, a subsidiary of Centrient Pharmaceuticals International B.V.. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 19 January 1993 and has been in existence for over 33 years.
The company is registered with the Registrar of Companies (ROC), Chandigarh, under CIN U24231PB1993PTC023090. Its GSTIN is 03AABCM4314K1ZT (Punjab). The company holds 12 GST registrations, of which 5 are active.
The company has an authorised share capital of ₹170 Cr and a paid-up capital of ₹160.3 Cr. It was formerly known as Dsm Sinochem Pharmaceuticals India Limited and Dsm Anti Infectives India Private Limited. It is led by directors Namit Joshi (Whole-Time Director) and Devesh Prakash Srivastava (Whole-Time Director).
Its last annual general meeting (AGM) was held on 10 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Bhai Mohan Singh Nagar, Toansa, Punjab, India – 144533.
As per the financials filed for FY 2025, the company reported a revenue of ₹2,240.1 Cr, a growth of 8% compared to the previous year. For the same year it recorded a net profit of ₹64.76 Cr (net margin 2.9%) and EBITDA of ₹156.96 Cr (EBITDA margin 7%). Revenue has grown at a compounded annual rate (CAGR) of 11% over three years and 8% over five years.
The company has about 613 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Centrient Pharmaceuticals. As per MCA filings, the company has open charges of ₹200 Cr on record. Court records list 99 cases involving the company, including 53 filed by the company and 47 filed against it; 23 cases are pending. The company has 10 deals on record (8 secondary share transfers, 2 rights issues); the latest was in September 2017. Its 10 peer companies in the Pharma industry (API Manufacturers, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 5 smaller; the largest is Dishman Carbogen Amcis Limited with revenue of ₹2,733.18 Cr. The company has 26 MSME Form 1 returns on record between 2017 and 2024, listing 2,391 overdue payments to 122 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website centrient.com.
Company details
Name history
Centrient Pharmaceuticals India has undergone 6 name changes throughout its history. The current legal name is Centrient Pharmaceuticals India Private Limited.
| Company Name | Status |
|---|---|
| Centrient Pharmaceuticals India Private Limited | Current |
| Dsm Sinochem Pharmaceuticals India Limited | Previous |
| Dsm Anti Infectives India Private Limited | Previous |
| Max-Gb Private Limited | Previous |
| Dsm Anti Infectives India Limited | Previous |
| Dsm Sinochem Pharmaceuticals India Private Limited | Previous |
| Max-Gb Limited | Previous |
CIN history
Centrient Pharmaceuticals India has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U24231PB1993PTC023090, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24231PB1993PTC023090 | Current |
| U24231PB1999PLC023090 | Previous |
| U24231PB1999PTC023090 | Previous |
Contact details
Centrient Pharmaceuticals India Private Limited's registered office is in Toansa, Punjab. Its website is centrient.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressBhai Mohan Singh Nagar, Toansa, Punjab, India – 144533
- IndustryPharma, Drug Formulation & Development, API Manufacturers
To see the full contact details of Centrient Pharmaceuticals India Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Centrient Pharmaceuticals India operates one associated brand: Centrient Pharmaceuticals. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Active pharmaceutical ingredients and finished dosage forms are manufactured. | centrient.com |
Business activity
The main business activities of Centrient Pharmaceuticals India are manufacturing and trade. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products and wholesale trading. 2 activity segments are registered with the MCA.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | |
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Centrient Pharmaceuticals India Private Limited, buy the company report.
Financials of Centrient Pharmaceuticals India Private Limited
FY 2025 filings availableCentrient Pharmaceuticals India Private Limited reported revenue of ₹2,240.1 Cr (up 8% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 8% over five years, including 8% growth in the latest year. EBITDA rose 3% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹156.96 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹64.76 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 7% | ||||
| Net Profit Margin | 2.9% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Centrient Pharmaceuticals India Private Limited, buy the company report.
Board of directors and KMP of Centrient Pharmaceuticals India Private Limited
Centrient Pharmaceuticals India Private Limited currently reports 2 directors and 1 key managerial person. 26 former directors have served the organization.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Namit Joshi | Whole-Time Director | 29 Jul 2021 | 5 Years 3 Months | Current |
| Vikram Aditya Sehgal | Cfo | 04 Jun 2021 | 5 Years 4 Months | Current |
| Devesh Prakash Srivastava | Whole-Time Director | 01 Apr 2023 | 3 Years 6 Months | Current |
Peer comparison
Centrient Pharmaceuticals India Private Limited is compared with the 10 companies closest to it by revenue in the Pharma industry (API Manufacturers, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Dishman Carbogen Amcis Limited | ₹2,733.18 Cr (FY 2025) | 3.0% | Ahmedabad, Gujarat, India | |||
| Covalent Laboratories Private Limited | ₹2,693.24 Cr (FY 2025) | -8.0% | Hyderabad, Telangana, India | |||
| Honour Lab Limited | ₹2,482.63 Cr (FY 2025) | 4.0% | Hyderabad, Telangana, India | |||
| Alivus Life Sciences Limited | ₹2,421.45 Cr (FY 2025) | 5.0% | Solapur, Maharashtra, India | |||
| Aarti Drugs Limited | ₹2,403.39 Cr (FY 2025) | -5.0% | Thane, Maharashtra, India | |||
| Centrient Pharmaceuticals India Private Limitedthis company | ₹2,240.1 Cr (FY 2025) | ₹64.76 Cr | 2.9% | 8.0% | 613 | Toansa, Punjab, India |
| Unichem Laboratories Limited | ₹2,146.29 Cr (FY 2025) | 18.0% | Mumbai, Maharashtra, India | |||
| Iol Chemicals and Pharmaceuticals Limited | ₹2,101.62 Cr (FY 2025) | -3.0% | Barnala, Punjab, India | |||
| Tianish Laboratories Private Limited | ₹2,059.53 Cr (FY 2024) | Hyderabad, Telangana, India | ||||
| Pfizer Healthcare India Private Limited | ₹1,981.45 Cr (FY 2025) | 4.0% | Chennai, Tamil Nadu, India | |||
| MSN Life Sciences Private Limited | ₹1,961.87 Cr (FY 2024) | 54.0% | Hyderabad, Telangana, India |
To see the full peer comparison of Centrient Pharmaceuticals India Private Limited, buy the company report.
Auditor
Centrient Pharmaceuticals India Private Limited is audited by MS K A & ASSOCIATES for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| MS K A & ASSOCIATES | FY 2023 | 105047W |
Shareholding
The shareholding of Centrient Pharmaceuticals India Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Centrient Pharmaceuticals India Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 31 Oct 2018 | 100212988 | Others | ₹200 Cr | Open |
To see the full charge records of Centrient Pharmaceuticals India Private Limited, buy the company report.
Total charge records: 1 View all charges
Deals & funding
Centrient Pharmaceuticals India Private Limited has 10 deals on record (8 secondary share transfers, 2 rights issues); the latest was in September 2017.
Deals on record (5 of 10)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2017 | Secondary share transfer | Undisclosed | Buyer: Gist Brocades International B.V., an individual Seller: 2 individuals |
| Sep 2016 | Secondary share transfer | Undisclosed | Buyer: 3 individuals Seller: 4 individuals |
| Sep 2013 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Sep 2012 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: 4 individuals |
| Sep 2011 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
To see the full deal history of Centrient Pharmaceuticals India Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Centrient Pharmaceuticals India Private Limited has 99 court cases on record: 53 filed by Centrient Pharmaceuticals India, 47 filed against it. 23 cases are pending and 76 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 68 | 26 | 20 |
| District courts | 23 | 16 | 2 |
| Supreme Court | 6 | 5 | 0 |
| NCLT | 2 | 0 | 1 |
Cases on record (5 of 99)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court, PUNJAB | Writ petition | Filed against the company by Centrient Pharmaceuticals India Private Limited and 1 other | Pending |
| High Court, PUNJAB | Writ petition | Filed by the company against Centrient Pharmaceuticals India Private Limited and 3 others | Pending |
| Supreme Court | Court case (1100-Arbitration Matters : SLPs challenging Arbitration Matters) | Filed against the company by Hindustan Antibiotics Ltd. Through Its Authorized Officer, Vinay Kumar Mishra Office at: Pimpri, Pune 411 018 ,Pune , Maharashtra | Disposed |
| High Court, MAHARASHTRA | Writ petition | Filed by the company against Hindustan Antibiotics Ltd. | Disposed |
| High Court, PUNJAB | Revision petition | Filed against the company by Hindustan Antibiotics Ltd | Disposed |
To see the full case history of Centrient Pharmaceuticals India Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Centrient Pharmaceuticals India Private Limited was last rated by Crisil on 19 Oct 2018.
| Rating agency | Rated on | Rating |
|---|---|---|
| Crisil | 19 Oct 2018 |
To see the full credit ratings and regulatory alerts of Centrient Pharmaceuticals India Private Limited, buy the company report.
MSME payment delays
Centrient Pharmaceuticals India Private Limited has 26 MSME Form 1 returns on record between 2017 and 2024, listing 2,391 overdue payments to 122 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 122)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| Euro Containers | |||
| Rajindra Carbons | |||
| SFC Cold Chain Logistics Private Limited | |||
| Kaila Engineering Pvt Ltd |
To see the full MSME payment records of Centrient Pharmaceuticals India Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Centrient Pharmaceuticals India Private Limited has a workforce of 613 employees on its EPFO records as of Mar 23, 2024, across 1 active EPFO establishment.
GST
Centrient Pharmaceuticals India has 12 GST registrations: 5 active and 7 cancelled or inactive. The first 4 active GSTINs are listed below.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 03AABCM4314K1ZT | Punjab | Active | 01 Jul 2017 |
| 06AABCM4314K1ZN | Haryana | Active | 01 Jul 2017 |
| 27AABCM4314K1ZJ | Maharashtra | Active | 01 Jul 2017 |
| 36AABCM4314K1ZK | Telangana | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Centrient Pharmaceuticals India Private Limited, buy the company report.
Recent activity
Centrient Pharmaceuticals India Private Limited has 27 board changes on record since 2009: 3 appointments and 24 cessations. The latest: Devesh Prakash Srivastava ceased to be Additional Director on 17 Sep 2023.
20 earlier events are in the company report.
Frequently asked questions
Centrient Pharmaceuticals India is an active private limited company based in Toansa, Punjab, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 19 January 1993 (33+ years old) and is registered under CIN U24231PB1993PTC023090.
Centrient Pharmaceuticals India has 3 current directors and KMP:
- Namit Joshi - Whole-Time Director
- Devesh Prakash Srivastava - Whole-Time Director
- Vikram Aditya Sehgal - Cfo
The latest financial statements of Centrient Pharmaceuticals India on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 10 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Centrient Pharmaceuticals India is 03AABCM4314K1ZT, registered in Punjab. The company has 12 GST registrations in all, of which 5 are active and 7 are cancelled or inactive. Other active GSTINs include 06AABCM4314K1ZN (Haryana), 27AABCM4314K1ZJ (Maharashtra), 36AABCM4314K1ZK (Telangana).
The CIN (Corporate Identification Number) of Centrient Pharmaceuticals India is U24231PB1993PTC023090. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Centrient Pharmaceuticals India has 99 court cases on record: 53 filed by the company and 47 filed against it. 23 are pending. Most are in the high courts.
Centrient Pharmaceuticals India was incorporated on 19 January 1993, making it 33+ years old. It is registered with the Registrar of Companies, Chandigarh.
Centrient Pharmaceuticals India has 10 deals on record (8 secondary share transfers, 2 rights issues); the latest was in September 2017.
The peers of Centrient Pharmaceuticals India by revenue are Dishman Carbogen Amcis Limited, Covalent Laboratories Private Limited, Honour Lab Limited, Alivus Life Sciences Limited, Aarti Drugs Limited and 5 more, all in the Pharma industry (API Manufacturers, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Devesh Prakash Srivastava ceased to be Additional Director on 17 Sep 2023. Devesh Prakash Srivastava was appointed as Whole-Time Director on 01 Apr 2023. Manoj Kumar Sharma ceased to be Additional Director on 14 Sep 2022. Centrient Pharmaceuticals India has 27 board changes on record in total.
Centrient Pharmaceuticals India has 26 MSME Form 1 returns on record between 2017 and 2024, listing 2,391 overdue payments to 122 micro and small suppliers. The latest return was filed on 29 Apr 2024.
Centrient Pharmaceuticals India can be reached through the website centrient.com. Its registered office is in Toansa, Punjab, India.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
